Clinical Center; Notice of Closed Meeting, 24318 [2018-11212]
Download as PDF
<![CDATA[
24318
Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices
amozie on DSK3GDR082PROD with NOTICES1
the need for childhood vaccination
products that result in fewer or no
significant adverse reactions; surveying
federal, state, and local programs and
activities related to gathering
information on injuries associated with
the administration of childhood
vaccines, including the adverse reaction
reporting requirements of section 2125
(b) of the PHS Act; advising the
Secretary on the methods of obtaining,
compiling, publishing, and using
credible data related to the frequency
and severity of adverse reactions
associated with childhood vaccines;
consulting on the development or
revision of Vaccine Information
Statements; and recommending to the
Director of the National Vaccine
Program research related to vaccine
injuries which should be conducted to
carry out the VICP.
Agenda: During the June 15, 2018,
meeting, agenda items may include
updates from DICP, Department of
Justice (DOJ), National Vaccine Program
Office (NVPO), Immunization Safety
Office (Centers for Disease Control and
Prevention), National Institute of
Allergy and Infectious Diseases
(National Institutes of Health) and
Center for Biologics, Evaluation and
Research (Food and Drug
Administration). Information about the
ACCV, a roster of members, the meeting
agenda, as well as past meeting
summaries, is located on the ACCV
website: https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html. Agenda items are subject to
change as priorities dictate.
Public Participation: Members of the
public will have the opportunity to
provide comments. Oral comments will
be honored in the order they are
requested and may be limited as time
allows. Requests to make oral comments
or provide written comments to the
ACCV should be sent to Annie Herzog
by June 5, 2018. Individuals who plan
to participate and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify Annie
Herzog, using the address and phone
number above at least 10 days prior to
the meeting.
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Clinical Center; Notice of Closed
Meeting
Prospective Grant of Exclusive
License: Production of Monovalent
Live Attenuated Zika Vaccines and
Multivalent Live Attenuated Flavivirus
Vaccines
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors of the NIH Clinical Center.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
CLINICAL CENTER, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors of the NIH Clinical Center Board
meeting.
Date: June 15, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate reports
and responses to the following Clinic
Center’s Departments: Rehabilitation
Medicine, Bioethics, Critical Care Medicine,
Imaging Sciences, Transfusion Medicine,
Laboratory Medicine, Nursing, and
Pediatrics.
Place: National Institutes of Health,
Building 10, 10 Center Drive, Bethesda, MD
20892.
Contact Person: John I. Gallin, M.D.,
Associate Director for Clinical Research,
Office of Director, NIH Clinical Center, 1
Center Drive, Room 201, Bethesda, MD
20892, 301–827–5428.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Dated: May 18, 2018.
Michelle D. Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–11212 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2018–11298 Filed 5–24–18; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
18:28 May 24, 2018
Jkt 241001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
National Institute of Allergy
and Infectious Diseases, National
Institutes of Health, Public Health
Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to to
Fundacao Butantan, having a place of
business in Sao Paulo, Brazil.
DATES: Only written comments and/or
application for a license which are
received by the NIAID Technology
Transfer and Intellectual Property Office
on or before June 25, 2018 will be
considered.
Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated Exclusive
Commercialization Patent License
should be directed to: Peter Soukas,
Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, National Institutes of Health,
5601 Fishers Lane, Suite 6D, Rockville,
MD 20852–9804; Email: ps193c@
nih.gov; Telephone: (301) 496–2644;
Facsimile: (240) 627–3117.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
U.S. Provisional Patent Application
Number 62/307,170, filed March 11,
2016 and entitled ‘‘Live Attenuated Zika
Virus Vaccines,’’ Whitehead et al., and
PCT Patent Application Number PCT/
US2017/0021989, filed March 11, 2017
and entitled ‘‘Live Attenuated Zika
Virus Vaccines,’’ Whitehead et al. [HHS
Reference E–118–2016/0]; and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Page 24318]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-11212]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Board of Scientific
Counselors of the NIH Clinical Center.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the CLINICAL
CENTER, including consideration of personnel qualifications and
performance, and the competence of individual investigators, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Board of Scientific Counselors of the NIH
Clinical Center Board meeting.
Date: June 15, 2018.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate reports and responses to the
following Clinic Center's Departments: Rehabilitation Medicine,
Bioethics, Critical Care Medicine, Imaging Sciences, Transfusion
Medicine, Laboratory Medicine, Nursing, and Pediatrics.
Place: National Institutes of Health, Building 10, 10 Center
Drive, Bethesda, MD 20892.
Contact Person: John I. Gallin, M.D., Associate Director for
Clinical Research, Office of Director, NIH Clinical Center, 1 Center
Drive, Room 201, Bethesda, MD 20892, 301-827-5428.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Dated: May 18, 2018.
Michelle D. Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-11212 Filed 5-24-18; 8:45 am]
BILLING CODE 4140-01-P
